Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers

BEA-28Positive

AI Analysis

Summary

Beactica Therapeutics AB announced the selection of BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers, as part of its TEAD programme development.

Outcome Details

BEA-28 selected as preclinical candidate for TEAD programme

Importance:3/10

Sentiment:

0.60

preclinicalTEAD degraderprecision medicinecancerfirst-in-class

Related Companies

$SHWZ $SOBI.ST $TRAX

Read the original article

Published by PR Newswire Pharma on October 6, 2026 6:21 AM

Read Original